MSD was able to receive the “Medicine of the Year” award

This year, the prestigious professional recognition of the Hungarian Society for Experimental and Clinical Pharmacology was earned by a drug developed for the prevention of dangerous viral infections, which often occur in adults who have undergone allogeneic stem cell transplantation. In Hungary, the award-winning product is now available with a unique fairness claim, which, according to clinical trials among stakeholders, significantly reduces the risk of recurrence of CMV infection, the development of serious, often fatal complications, and improves patients’ chances of survival.

More than half of the population is largely asymptomatic of CMV (cytomegalovirus) infections in the family of herpes viruses, but the pathogen remains in the body so it can be resurrected, attacked1. In healthy people, this usually does not require treatment, in contrast, patients who have undergone organ transplantation receive treatment that weakens their immune system, and the immune function of bone marrow transplant patients is already impaired. Thus, in this group, CMV can already cause serious or even fatal complications. MSD’s award-winning product is a breakthrough because in the past, only a small number of medicines were available in Hungary for the treatment of emerging diseases, not for prevention. The side effects of this highly innovative drug, which limit its applicability, are not yet known.

“It is a great honor and serious professional recognition that after 1996, 2002, 2006 and 2017, MSD was the only company to win the“ Drug of the Year ”award of the Hungarian Society of Experimental and Clinical Pharmacology for the fifth time. There has never been an example of this in Hungary before, we are proud of the recognition ” – said Dr. Szabolcs Barótfi – clinical research director of MSD.

On the awarding of the prize

“When awarding the Medicinal Product of the Year award, the main aspects of the evaluation are the novelty of the mechanism of action, the breakthrough of scientific discovery, the role of the drug in Hungary in the given therapeutic area, favorable side effects and interaction profiles, favorable metabolism and pharmacokinetics, the added value of domestic research and development ”said Prof. Dr. Péter Ferdinandy, President of MFT, Vice-Chancellor of Science and Innovation at Semmelweis University, Director of the Institute of Pharmacology and Pharmacotherapy.

“MSD was able to win the“ Drug of the Year ”award in Hungary again because the proposed product allows the prevention of this serious complication even in conditions characterized by reduced immunity. Innovative molecule with new mechanism of action has selective anti-cytomegalovirus activity ” said Prof. Dr. István Bitter, Chairman of the Professional Evaluation Committee of MFT, Chairman of the Clinical Pharmacology Ethics Committee of the Health Science Council, Professor Emeritus of the Department of Psychiatry and Psychotherapy, Semmelweis University. – „Nevertheless, the treatment is also free from the serious (toxic) side effects that have characterized the preventive treatments used so far – e.g. in the case of allogeneic stem cell transplantation. Data published in the literature confirmed the prophylactic efficacy of the drug and also documented the reduction in mortality. ” – added Prof. Dr. István Bitter.

The Hungarian Society of Experimental and Clinical Pharmacology presented the “Medicine of the Year” award to the winner, MSD Pharma Hungary Kft., On June 24 this year at a solemn and press event.


1 Varga M, Görög D, Kári D, et al. Cytomegalovirus seroprevalence among solid organ donors in Hungary: correlations with age, gender, and blood group. Transplant Proc. 2011 May;43(4):1233-5. doi: 10.1016/j.transproceed.2011.03.067. PMID: 21620098.

Source: Patika Magazin Online by

*The article has been translated based on the content of Patika Magazin Online by If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!